
KZIA
Healthcare · Biotechnology · $75.6M market cap
$6.59-0.35 (-5.1%)Nov 13, 4:00 PM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Mar 31, 2026
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 6, 2026 | Time not confirmed | — | — | — |
| Nov 7, 2025 | Time not confirmed | -221.00 | -7.64 | +96.5% |
| Jun 10, 2025 | Time not confirmed | — | -12.30 | — |
| Nov 15, 2024 | Time not confirmed | — | -31.22 | — |
| Jun 30, 2021 | Time not confirmed | 0.00 | -0.01 | — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.01 | — |
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.02 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.03 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.03 | — |
| Sep 30, 2019 | Time not confirmed | 0.00 | -0.03 | — |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.02 | — |
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat…
| Mar 31, 2019 |
| Time not confirmed |
| 0.00 |
| -0.02 |
| — |
| Dec 31, 2018 | Time not confirmed | 0.00 | -0.04 | — |
| Sep 30, 2018 | Time not confirmed | 0.00 | -0.04 | — |
| Jun 30, 2018 | Time not confirmed | 0.00 | -0.05 | — |
| Feb 21, 2018 | Time not confirmed | — | 0.01 | — |